Therapeutic Landscape Evolution: From Lifestyle Interventions to Precision Pharmacotherapy - PubMed
19 hours ago
- #Steatotic Liver Disease
- #Precision Medicine
- #Pharmacotherapy
- Steatotic liver disease (SLD), especially metabolic dysfunction-associated SLD (MASLD), is now the most prevalent chronic liver disease globally, closely tied to cardiovascular risks.
- Lifestyle changes, particularly the Mediterranean diet, are foundational treatments, with new evidence supporting other dietary and exercise approaches.
- Two FDA-approved drugs, resmetirom and semaglutide, are available for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, with many more drugs targeting various mechanisms under development.
- For metabolic dysfunction- and alcohol-associated liver disease (MetALD), management prioritizes alcohol cessation and controlling cardiometabolic factors, with potential therapies like resmetirom, incretin-based treatments, and FGF-21 analogues awaiting full clinical trial evaluation.
- The field is shifting towards precision medicine that combines lifestyle and drug interventions, customized by disease type, genetics, and gut microbiome, despite challenges like varied treatment responses and implementation issues.